Betulinic acid derivatives NVX-207 and B10 for treatment of glioblastoma—an in vitro study of cytotoxicity and radiosensitization

International Journal of Molecular Sciences

Volumn 15, Issue 11, 2014, Pages 19777-19790

  Bache, Matthias ^a   Bernhardt, Stephan ^a,b   Passin, Sarina ^a   Wichmann, Henri ^a   Hein, Anja ^a   Zschornak, Martin ^a   Kappler, Matthias ^a   Taubert, Helge ^c   Paschke, Reinhard ^a   Vordermark, Dirk ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Betulinic acid derivatives; Cytotoxicity; Glioma; Hypoxia; Irradiation; Normoxia

Indexed keywords

28 O ACETYL BETULIN 3 YL BETA D GLUCOPYRANOSIDE; 3 ACETYL BETULINIC ACID 2 AMINO 3 HYDROXY 2 HYDROXYMETHYL PROPANOATE; BETA ACTIN; BETULIC ACID; CARBONATE DEHYDRATASE IX; CHEMICAL COMPOUND; DIMETHYL SULFOXIDE; LACTATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SULFORHODAMINE B; SURVIVIN; UNCLASSIFIED DRUG; 2-AMINO-3-HYDROXY-2-HYDROXYMETHYLPROPYL 3-ACETYLBETULINOATE; 28-O-ACETYLBETULIN-3-YLGLUCOPYRANOSIDE; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; GLUCOSIDE; INHIBITOR OF APOPTOSIS PROTEIN; PROPANOLAMINE DERIVATIVE; TRITERPENE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL COUNT; CELL MIGRATION ASSAY; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; HYPOXIA; IC50; IN VITRO STUDY; IRRADIATION; MIGRATION INHIBITION; NECROSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RADIOSENSITIVITY; RADIOSENSITIZATION; SCRATCH WOUND ASSAY; WESTERN BLOTTING; BRAIN TUMOR; CELL MOTION; CHEMISTRY; DRUG EFFECTS; IONIZING RADIATION; METABOLISM; PATHOLOGY; RADIATION RESPONSE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; GLIOBLASTOMA; GLUCOSIDES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; POLY(ADP-RIBOSE) POLYMERASES; PROPANOLAMINES; RADIATION, IONIZING; TRITERPENES;

EID: 84908331697     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151119777     Document Type: Article

References (33)

1. Kortmann, R.D.; Jeremic, B.; Weller, M.; Plasswilm, L.; Bamberg, M. Radiochemotherapy of malignant glioma in adults. Clinical experiences. Strahlenther. Onkol. 2003, 179, 219-232.
2. Henriksson, R.; Asklund, T.; Poulsen, H.S. Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: A review. J. Neurooncol. 2011, 104, 639-646.
3. Nieder, C.; Mehta, M.P. Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma. Med. Hypotheses 2011, 76, 410-413.
4. Shirai, K.; Chakravarti, A. Towards personalized therapy for patients with glioblastoma. Expert Rev. Anticancer Ther. 2011, 11, 1935-1944.
5. Alakurtti, S.; Mäkelä, T.; Koskimies, S.; Yli-Kauhaluoma, J. Pharmacological properties of the ubiquitous natural product betulin. Eur. J. Pharm. Sci. 2006, 29, 1-13.
6. Kessler, J.H.; Mullauer, F.B.; de Roo, G.M.; Medema, J.P. Broad in vitro efficacy of plant-derived betulinic acid against cell lines derived from the most prevalent human cancer types. Cancer Lett. 2007, 251, 132-145.
7. Fulda, S.; Jeremias, I.; Steiner, H.H.; Pietsch, T.; Debatin, K.M. Betulinic acid: A new cytotoxic agent against malignant brain-tumor cells. Int. J. Cancer 1999, 82, 435-441.
8. Wick, W.; Grimmel, C.; Wagenknecht, B.; Dichgans, J.; Weller, M. Betulinic acid-induced apoptosis in glioma cells: A sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. J. Pharmacol. Exp. Ther. 1999, 289, 1306-1312.
9. Jeremias, I.; Steiner, H.H.; Benner, A.; Debatin, K.M.; Herold-Mende, C. Cell death induction by betulinic acid, ceramide and TRAIL in primary glioblastoma multiforme cells. Acta Neurochir. 2004, 146, 721.
10. Fulda, S.; Debatin, K.M. Sensitization for anticancer drug-induced apoptosis by betulinic acid. Neoplasia 2005, 7, 162-170.
11. Jung, G.R.; Kim, K.J.; Choi, C.H.; Lee, T.B.; Han, S.I.; Han, H.K.; Lim, S.C. Effect of betulinic acid on anticancer drug-resistant colon cancer cells. Basic. Clin. Pharmacol. Toxicol. 2007, 101, 277-285.
12. Selzer, E.; Pimentel, E.; Wacheck, V.; Schlegel, W.; Pehamberger, H.; Jansen, B.; Kodym, R. Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J. Investig. Dermatol. 2000, 114, 935-940.
13. Eder-Czembirek, C.; Erovic, B.M.; Czembirek, C.; Brunner, M.; Selzer, E.; Pötter, R.; Thurnher, D. Betulinic acid a radiosensitizer in head and neck squamous cell carcinoma cell lines. Strahlenther. Onkol. 2010, 186, 143-148.
14. Bache, M.; Zschornak, M.P.; Passin, S.; Kessler, J.; Wichmann, H.; Kappler, M.; Paschke, R.; Kaluđerović, G.N.; Kommera, H.; Taubert, H.; et al. Increased betulinic acid induced cytotoxicity and radiosensitivity in glioma cells under hypoxic conditions. Radiat. Oncol. 2011, 6, 111.
15. Kumar, V.; Rani, N.; Aggarwal, P.; Sanna, V.K.; Singh, A.T.; Jaggi, M.; Joshi, N.; Sharma, P.K.; Irchhaiya, R.; Burman, A.C. Synthesis and cytotoxic activity of heterocyclic ring-substituted betulinic acid derivatives. Bioorg. Med. Chem. Lett. 2008, 18, 5058-5062.
16. Bar, F.M.; Khanfar, M.A.; Elnagar, A.Y.; Liu, H.; Zaghloul, A.M.; Badria, F.A.; Sylvester, P.W.; Ahmad, K.F.; Raisch, K.P.; el Sayed, K.A. Rational design and semisynthesis of betulinic acid analogues as potent topoisomerase inhibitors. J. Nat. Prod. 2009, 72, 1643-1650.
17. Santos, R.C.; Salvador, J.A.; Marín, S.; Cascante, M. Novel semisynthetic derivatives of betulin and betulinic acid with cytotoxic activity. Bioorg. Med. Chem. 2009, 17, 6241-6250.
18. Smith, P.F.; Ogundele, A.; Forrest, A.; Wilton, J.; Salzwedel, K.; Doto, J.; Allaway, G.P.; Martin, D.E. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob. Agents Chemother. 2007, 51, 3574-3581.
19. Willmann, M.; Wacheck, V.; Buckley, J.; Nagy, K.; Thalhammer, J.; Paschke, R.; Triche, T.; Jansen, B.; Selzer, E. Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound. Eur. J. Clin. Investig. 2009, 39, 384-394.
20. Gauthier, C.; Legault, J.; Lebrun, M.; Dufour, P.; Pichette, A. Glycosidation of lupane-type triterpenoids as potent in vitro cytotoxic agents. Bioorg. Med. Chem. 2006, 14, 6713-6725.
21. Kommera, H.; Kaluderović, G.N., Bette, M.; Kalbitz, J.; Fuchs, P.; Fulda, S.; Mier, W.; Paschke, R. In vitro anticancer studies of α-and β-D-glucopyranose betulin anomers. Chem. Biol. Interact. 2010, 185, 128-136.
22. Gonzalez, P.; Mader, I.; Tchoghandjian, A.; Enzenmüller, S.; Cristofanon, S.; Basit, F.; Debatin, K.M.; Fulda, S. Impairment of lysosomal integrity by B10, a glycosylated derivative of betulinic acid, leads to lysosomal cell death and converts autophagy into a detrimental process. Cell Death Differ. 2012, 19, 1337-1346.
23. Kommera, H.; Kaluderović, G.N.; Kalbitz, J.; Dräger, B.; Paschke, R. Small structural changes of pentacyclic lupane type triterpenoid derivatives lead to significant differences in their anticancer properties. Eur. J. Med. Chem. 2010, 45, 3346-3353.
24. Mullauer, F.B.; Kessler, J.H.; Medema, J.P. Betulinic acid, a natural compound with potent anticancer effects. Anticancer Drugs 2010, 21, 215-227.
25. Goff, R.D; Thorson, J.S. Enhancing the divergent activities of betulinic acid via neoglycosylation. Org. Lett. 2009, 11, 461-464.
26. Enzenmüller, S.; Gonzalez, P.; Karpel-Massler, G.; Debatin, K.M.; Fulda, S. GDC-0941 enhances the lysosomal compartment via TFEB and primes glioblastoma cells to lysosomal membrane permeabilization and cell death. Cancer Lett. 2013, 329, 27-36.
27. Fischer, S.; Ronellenfitsch, M.W.; Thiepold, A.L.; Harter, P.N.; Reichert, S.; Kögel, D.; Paschke, R.; Mittelbronn, M.; Weller, M.; Steinbach, J.P.; et al. Hypoxia enhances the antiglioma cytotoxicity of b10, a glycosylated derivative of betulinic acid. PLoS One 2014, 9, e94921.
28. Karna, E.; Szoka, L.; Palka, J.A. Betulinic acid inhibits the expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in human endometrial adenocarcinoma cells. Mol. Cell. Biochem. 2010, 340, 15-20.
29. Shin, J.; Lee, H.J.; Jung, D.B.; Jung, J.H.; Lee, H.J.; Lee, E.O.; Lee, S.G.; Shim, B.S.; Choi, S.H.; Ko, S.G.; et al. Suppression of STAT3 and HIF-1α mediates anti-angiogenic activity of betulinic acid in hypoxic PC-3 prostate cancer cells. PLoS One 2011, 6, e21492.
30. Dehelean, C.A.; Feflea, S.; Ganta, S.; Amiji, M. Anti-angiogenic effects of betulinic acid administered in nanoemulsion formulation using chorioallantoic membrane assay. J. Biomed. Nanotechnol. 2011, 7, 317-324.
31. Ishii, N.; Maier, D.; Merlo, A.; Tada, M.; Sawamura, Y.; Diserens, A.C.; van Meir, E.G. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 1999, 9, 469-479.
32. Berger, B.; Capper, D.; Lemke, D.; Pfenning, P.N.; Platten, M.; Weller, M.; von Deimling, A.; Wick, W.; Weiler, M. Defective p53 antiangiogenic signaling in glioblastoma. Neuro Oncol. 2010, 12, 894-907.
33. Kappler, M.; Rot, S.; Taubert, H.; Greither, T.; Bartel, F.; Dellas, K.; Hänsgen, G.; Trott, K.R.; Bache, M. The effects of knockdown of wild-type survivin, survivin-2B or survivin-delta3 on the radiosensitization in a soft tissue sarcoma cells in vitro under different oxygen conditions. Cancer Gene Ther. 2007, 14, 994-1001.